Future Directions
The Cambridge researchers are now collaborating with Professor Ruth Langley, who is leading the Add-Aspirin clinical trial, to determine if aspirin can stop or delay the recurrence of early-stage cancers. This trial is enrolling patients with breast, bowel, and prostate cancers who have already undergone standard treatments.The results of the Add-Aspirin trial will provide valuable information on the efficacy and safety of aspirin in preventing cancer recurrence.
These findings will help to guide clinical practice and inform the development of new strategies for cancer prevention and treatment. In addition to clinical trials, future research will focus on identifying other drugs that can target the TXA2-ARHGEF1 pathway and enhance T-cell function. These drugs may offer a more targeted and effective approach to preventing cancer metastasis with fewer side effects than aspirin.